Research and Markets - Global Central Nervous System Disorders Therapeutics Market CAGR Growth of 3.38% by 2020 - Trends, Technologies & Opportunities Report 2016-2020 - Vendors: Opexa, Mylan, Eli Lilly

DUBLIN, October 7, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Central Nervous System Disorders Therapeutics Market 2016-2020" report to their offering.

The global central nervous system (CNS) disorders therapeutics market is forecast to grow at a CAGR of 3.38% during the period 2016-2020.

According to the report, high growth potential of mAbs will be a key driver for market growth. The understanding of a disease at the molecular level increases the development and use of biologics in the treatment. Biologics have a high affinity toward specific disease cells. Biologics account for over 18% of the global pharmaceutical sales, outpacing the sales of branded pharmaceuticals.

They will continue to out-perform pharmaceuticals in terms of product sales, as there is an increasing need for effective treatment options. Biologics that treat musculoskeletal disorders are made from proteins. Their MOA is inhibiting the action of key chemicals or cells involved in the nervous system. Few of the mAbs used to treat CNS disorders are natalizumab, daclizumab, and alemtuzumab. Other than these mAbs, many are in various stages of the pipeline for the treatment of CNS disorders.

Further, the report states that the activities of the brain are continuously monitored by RNS system, and when any patterns that could lead to seizures are detected, the neurostimulator sends brief impulses and disrupts the abnormal brain activity. In addition, Medtronic developed Medtronic deep brain stimulation (DBS) therapy as an adjunctive treatment for partial-onset seizures in adults with medically refractory epilepsy.

Also, NeuroSigma is under the Phase III development of external trigeminal nerve stimulation (eTNS) for epilepsy, depression, attention deficit hyperactivity disorder (ADHD), post-traumatic stress disorder (PTSD), Lennox-Gastaut syndrome (LGS), and traumatic brain injury (TBI). The rise in research activities in the development of these devices along with their adoption for the treatment of seizures will act as a challenge for the global CNS disorders therapeutics market.

Questions Answered:

• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Companies Mentioned Include:

• GlaxoSmithKline
• Pfizer
• Eli Lilly
• Abital Pharma
• Aprecia Pharmaceuticals
• Archer Pharmaceuticals
• MSI Methylation Sciences
• Mylan
• Opexa
• Opko Health
• Par Pharmaceuticals
• SAGE Therapeutics
• Sanofi
• US WorldMeds
• Valeant Pharmaceuticals
• Zinfandel Pharmaceuticals
• Zogenix

Report Structure:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Market research methodology

PART 04: Introduction

PART 05: Pipeline portfolio

PART 06: Market landscape

PART 07: Market segmentation by type of disease

PART 08: Geographical segmentation

PART 09: Market drivers

PART 10: Impact of drivers

PART 11: Market challenges

PART 12: Impact of drivers and challenges

PART 13: Market trends

PART 14: Vendor landscape

PART 15: Appendix

PART 16: About the Author

For more information about this report visit http://www.researchandmarkets.com/research/vcmg7j/global_central

Media Contact:

Research and Markets

Laura Wood, Senior Manager

[e-mail]

For E.S.T Office Hours Call [phone]

For U.S./CAN Toll Free Call [phone]

For GMT Office Hours Call [phone]

U.S. Fax: [phone]

Fax (outside U.S.): [phone]